Exelixis Announces Third Quarter 2023 Financial Results and

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -- Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on...

Related Keywords

New York , United States , Delaware , Chris Senner , Amy Peterson , Susan Hubbard , Michaelm Morrissey , Alliance For Clinical Trials In Oncology , Us District Court , Genentech , Thomas Jefferson University , Takeda Pharmaceutical Company , University Of Chicago , Share Repurchase Program , Teva Pharmaceuticals , National Cancer Institute , Exchange Commission , Product Development Medical Affairs , Drug Administration , European Society For Medical Oncology , Facebook , International Kidney Cancer Symposium , Nasdaq , Teva Pharmaceuticals United States Inc , Teva Pharmaceuticals Development Inc , Exelixis Inc , Product Revenues , Webcast Today , Chief Executive Officer , Chief Medical Officer , Kidney Cancer Symposium , Insilico Medicine , Ipsen Pharma , Accepted Accounting Principles , Franchise Net Product Revenues , Trial Evaluating Cabozantinib , Metastatic Castration Resistant Prostate Cancer , Advanced Pancreatic , Extra Pancreatic Neuroendocrine Tumors Presented , Medical Oncology , Clinical Trials , Safety Monitoring Board , Interim Analysis , License Agreement , Teva Pharmaceuticals Development , Teva Pharmaceuticals United States , Abbreviated New Drug Application , Executive Vice President , Product Development , Medical Affairs , Chief Medical , Northwestern Memorial Hospital , Exclusive Global License Agreement , Potentially Best In Class , Event Calendar , Annual Report , Quarterly Reports , Months Ended September ,